Physician profile
Mary Poonen
NPI 1780675256
$11,303.73
in general payments reported to CMS, 2019-2025
15 companies · $2,742 in 2025
The $2,742 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,548 · 2020: $726 · 2021: $421 · 2022: $1,016 · 2023: $769 · 2024: $2,081 · 2025: $2,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,577 · Travel and Lodging: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,577.38 |
| Travel and Lodging | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,924.15 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $2,244.36 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $1,702.28 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $948.78 | 2024-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $778.67 | 2019-2025 | Ingrezza |
| Allergan, INC. | $684.91 | 2019-2020 | |
| Abbvie INC. | $472.93 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.37 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $336.42 | 2019-2020 | |
| Indivior INC. | $240.08 | 2019-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $227.74 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $151.57 | 2019 | |
| Janssen Scientific Affairs, LLC | $144.43 | 2024-2025 | Invega Sustenna |
| Owp Pharmaceuticals, INC. | $46.19 | 2021 | |
| Sumitomo Pharma America, INC. | $29.85 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Poonen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.